Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJan102022	Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Antigen Binding Domain of FT536 has been Shown to Overcome MICA/B Read All »	View HTML
Toggle SummaryJul092020	Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO , July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Read All »	View HTML
Toggle SummaryAug022021	Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate Three Dosing Regimens of FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO , Aug. Read All »	View HTML
Toggle SummaryOct152020	Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting SAN DIEGO , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that five abstracts for the Company’s induced Read All »	View HTML
Toggle SummarySep302020	Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit SAN DIEGO , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate in a fireside chat Read All »	View HTML
Toggle SummaryMay062015	Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies Alliance Utilizes Fate's Hematopoietic Cell Programming Platform to Identify Small Molecule Modulators for Juno's Leading Genetically-Engineered T Cell Immunotherapies Read All »	View HTML Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies 27.1 KB
Toggle SummaryMay092011	Takeda Ventures Makes Strategic Investment in Fate Therapeutics Joins Strategic Investor Syndicate of Fate that Includes Four Pharmaceutical Companies Read All »	View HTML Takeda Ventures makes strategic investment in Fate Therapeutics 15.1 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.